456570.Kn
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and commercialization of diagnostic solutions.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and commercialization of diagnostic solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and commercialization of diagnostic solutions.
The company's capital structure is highly leveraged, with total liabilities of KRW 7.5 trillion and total equity of -KRW 6.0 trillion, resulting in a negative debt-to-equity ratio of -0.31. Despite holding KRW 6.1 billion in cash and equivalents, the company's liquidity remains constrained due to a current ratio of 0.18, indicating significant short-term financial pressure.
Profitability is severely challenged, with a net loss of KRW 39.97 billion and an operating loss of KRW 5.62 billion. The return on assets is negative at -2.64%, and the return on equity is 0.664, which is likely below industry medians for a profitable biotechnology firm. These metrics suggest the company is not generating sufficient returns to justify its capital deployment.
The company's revenue is not disclosed, and there is no segment or geographic breakdown provided in the available data. Without this information, it is difficult to assess the concentration of revenue or geographic exposure. However, the lack of segmental data implies a potential overreliance on a single product line or market.
Growth trajectory is not clearly defined due to the absence of historical revenue data. The company is currently reporting a net loss and negative operating cash flow, which may indicate a lack of sustainable growth or a high burn rate. The outlook for the current fiscal year is not provided, but the negative cash flow and operating performance suggest a challenging path forward.
The company faces significant financial risk, with a medium liquidity risk and a negative net cash position after subtracting total debt. The dilution risk is currently assessed as low, but the company's negative equity and high debt levels could necessitate future equity issuances, which would dilute existing shareholders. No specific dilution sources are disclosed in the available data.
There are no recent events or filings disclosed in the available data to provide insight into the company's strategic direction or operational developments. The absence of such information limits the ability to assess the company's response to market conditions or regulatory changes.
- The company is operating at a significant net loss and has negative equity, indicating severe financial distress.
- Liquidity is constrained, with a current ratio of 0.18 and negative net cash after debt.
- Profitability metrics are poor, with a negative return on assets and a return on equity that is not indicative of a healthy biotechnology firm.
- There is no segment or geographic revenue breakdown, suggesting a lack of diversification and potential overreliance on a single product or market.
- The company's growth trajectory is unclear, and there are no recent events or filings to provide insight into its strategic direction.
- **margin_outlook_rationale**: The company is currently reporting a net loss, and without a clear path to profitability, margin improvement is uncertain.
- **rd_outlook_rationale**: No specific information is available to assess the company's research and development outlook.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 456570.KN Market data — financials · 2026-05-26